Dr. Neelapu on FDA-Approved CAR T-Cell Products Spanning Lymphoma Subtypes

Video

Sattva Neelapu, MD, discusses CAR T-cell products that have been approved by the FDA for different subtypes of lymphoma.

Sattva Neelapu, MD, a professor of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses CAR T-cell products that have been approved by the FDA for different subtypes of lymphoma.

CAR T-cell therapy was initially approved by the FDA for patients who had relapsed/refractory large B-cell lymphomas, according to Neelapu. However, these therapies have since been investigated in early lines of therapy, as is being done in the phase 2 ZUMA-12 study (NCT03761056), as well as in other lymphoma subtypes, including mantle cell lymphoma (MCL) and indolent non-Hodgkin lymphoma (NHL).

At least 3 FDA-approved products have emerged for patients with relapsed/refractory large B-cell lymphoma in the third-line setting, Neelapu says. Additionally, brexucabtagene autoleucel (Tecartus; formerly KTE-X19) was approved by the FDA in July 2020 for use in adult patients with relapsed/refractory MCL.

Importantly, other ongoing clinical trials are examining other CAR T-cell therapies in patients with MCL or indolent NHL. Due to this, additional approvals are expected in the near future for these lymphoma subtypes, Neelapu concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.